SEC Form 4 · accession 0001780660-26-000019
Adaptive Biotechnologies Corp · ADPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francis Lo
Officer — Chief People Officer
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 7:23 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001478320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 15, 2026 | M | 59,374 | $7.80 | A | 290,087 | D | |
| Common Stock | Jul 15, 2026 | M | 23,677 | $12.14 | A | 313,764 | D | |
| Common Stock | Jul 15, 2026 | M | 22,711 | $8.46 | A | 336,475 | D | |
| Common StockF2 | Jul 15, 2026 | S | 105,762 | $22.59 | D | 230,713 | D | |
| Common Stock | holding | — | — | — | 2,500 | I | By You Jin Lee (spouse) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $7.80 | Jul 15, 2026 | M | 59,374 | D | — | May 6, 2029 | Common Stock | 59,374 | 0 | D |
| Stock Option (right to buy)F3 | $12.14 | Jul 15, 2026 | M | 23,677 | D | — | Mar 4, 2032 | Common Stock | 23,677 | 132,246 | D |
| Stock Option (right to buy)F4 | $8.46 | Jul 15, 2026 | M | 22,711 | D | — | Mar 6, 2033 | Common Stock | 22,711 | 37,511 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
- F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3The option is fully vested and exercisable.
- F4The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.